Purpose - With renewed greenhouse gas (GHG) emissions, abatement commitments and the rejoining of the Paris Climate Agreement of 2015 by the U.S., this study assesses the impact of carbon dioxide (CO₂) emissions reduction, and the opportunity cost of the U.S. in implementing its nationally determined commitments (NDCs).
Design/Methodology/Approach - The study employs the GTAP-E model, an extension of the static GTAP model with CO₂ emissions trading, and GTAP DB version 10A with a base year of 2014. Model implementation includes a baseline scenario that projects the global economy from 2014 to 2030, and four policy scenarios representing the implementation of U.S. NDC targets without and with emissions trading.
Findings - Simulation results suggest that CO₂ emissions reduction with trading significantly lowers the emissions abatement cost compared to CO₂ emissions reduction with no trading. Furthermore, the study finds that CO₂ emissions reduction leads to a drop in industry output by all energy and most non-energy sectors. Simulation results illustrate that CO₂ emissions reduction by the U.S. significantly affects most of its trading partners’ real GDPs, welfare, export and import flows, and industry outputs.
Research Implications - The study provides a comprehensive impact assessment of global CO₂ emissions reduction, including U.S. contributions to addressing climate change. Moreover, the study has quantified the opportunity cost the U.S. will likely pay for meeting its NDC targets, and the likely impact of CO₂ emissions reduction by the U.S. on its major trading partners, especially the EU, Korea, Japan, and China.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.